Skip to main content
International Journal of Bipolar Disorders logoLink to International Journal of Bipolar Disorders
. 2026 Mar 6;14:16. doi: 10.1186/s40345-026-00413-1

The association between psychotropic medications and cognitive functioning in bipolar disorder

Faith Dickerson 1,✉, Andrea Origoni 1, Emily Katsafanas 1, Kelly Rowe 1, Sabahat Khan 1, Allana Therese Calahatian 1, Fahad Mukhtar 1, Robert Yolken 2
PMCID: PMC13111742  PMID: 41787007

Abstract

Background

Many individuals with bipolar disorder have decreased levels of cognitive functioning even when in a euthymic mood state. Persons with bipolar disorder are usually treated with psychotropic agents, but the effects of these medications on their cognitive functioning have not been extensively studied.

Methods

A total of 567 people with bipolar disorder were assessed on a cognitive battery, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and Trail Making Test, part A (Trails A) and Letter-Number Sequencing. The machine-learning tool of cross-fit partialing-out least absolute shrinkage and selection operator (LASSO) regression was used to examine the independent association between the cognitive test scores and receipt of individual psychotropic medications considering relevant demographic and clinical covariates. Ordered logistic regression models were employed to examine the effects of medication dosage on the cognitive scores.

Results

We found that 3 medications, ziprasidone, benztropine, and clonazepam, were independently associated with significantly reduced cognitive scores compared with individuals not receiving these medications. Benztropine showed a significant dose-related relationship with all of the cognitive measures. Reduced memory and psychomotor speed were the domains most associated with receipt of these medications.

Conclusions

Prescribers may consider limiting the administration of the medications which can affect cognitive functioning. Interventions should be further developed for people with bipolar disorder to improve their cognitive functioning and quality of life.

Supplementary Information

The online version contains supplementary material available at 10.1186/s40345-026-00413-1.

Keywords: Cognitive, Psychopharmacology, Memory, Medications, Mood disorder

Background

As a group, people with bipolar disorder show impairment in cognitive functioning relative to age-matched controls, including persons in euthymic mood states (Torres et al. 2007; Kurtz and Gerraty 2009). These deficits are found across cognitive domains and are qualitatively similar, though less severe, than those found in individuals with schizophrenia (Schretlen et al. 2007; Dickerson et al. 2004a, b, c). Among persons with bipolar disorder, there is wide variability in cognitive functioning which cannot be fully explained by clinical subtype or symptom severity (Keramatian et al. 2021; Solé et al. 2017; Flaaten et al. 2024).

Cognitive deficits in bipolar disorder are associated with worse social and vocational outcomes and contribute to the disability associated with the disorder (Baune and Malhi 2015; Dickerson et al. 2004a, b, c). There are not any approved cognitive-enhancing medications for bipolar disorder. The lack of approval of medications stems from a lack of robust results confirming the benefit of medications for cognitive performance in clinical trials (Chen et al. 2021). Psychosocial cognitive remediation strategies may be effective for this population, but studies are limited, and these interventions can be difficult to apply in clinical practice (Samamé et al. 2023; Perra et al. 2025).

The association between psychotropic medications and cognitive performance in bipolar disorder has been the focus of some investigation, e.g. (Xu et al. 2020).,. Lithium, a mood stabilizer and mainstay of medication treatment for bipolar disorder, has been shown to have an adverse effect on psychomotor speed in some studies. However, findings are inconsistent and deficits, when found, appear to be mild (Mora et al. 2013; Paterson and Parker 2017) (Xu et al. 2020).

Second-generation antipsychotic medications are often prescribed to persons with bipolar disorder for their antimanic, mood stabilizing and antidepressant effects. Impairments in verbal memory have been found in persons with bipolar disorder receiving these antipsychotic medications vs. those who are not (Xu et al. 2020). This finding may be confounded by the fact that the subgroup receiving antipsychotics may have more severe psychiatric symptoms. There are few controlled studies examining the effect of antipsychotic medications in bipolar disorder (Daglas et al. 2016), though extensive studies have been performed in other psychiatric populations such as schizophrenia (Dickerson et al. 2025; Feber et al. 2025; Nielsen et al. 2015; Baldez et al. 2021). Medications such as anti-cholinergic agents may also be prescribed to treat the side effects of antipsychotic medications. The adverse cognitive effects of these agents are well-established (Joshi et al. 2021) but have received only limited investigation in bipolar disorder (Erdogan et al. 2025).

Other types of medications are also frequently prescribed to persons with bipolar disorder including anxiolytics and antidepressants to treat symptoms of depression, anxiety, and sleep disturbance. Investigations of the cognitive effects of benzodiazepines, a major class of anxiolytic medications, in bipolar disorder have been limited but suggest adverse effects (Cañada et al. 2021). Studies in the general population about the effect of benzodiazepines on cognition have had varied results (Edinoff et al. 2021). Similarly, the cognitive effects of antidepressants in bipolar disorder have received only little investigation (Xu et al. 2020), while studies of persons with depression suggest that these medications have a modest positive effect on cognitive functioning in this population (Prado et al. 2018).

Clinical and demographic factors may affect the degree of cognitive deficits in bipolar disorder (Xu et al. 2020). However, there are few studies about the association between psychotropic medications and cognitive functioning in bipolar disorder taking into account the possible effects of factors such as psychiatric symptom severity, illness history, educational status, exposure to environmental factors, and comorbid medical conditions. Furthermore, there are few studies which have examined the effects of medication dosage.

To address these gaps in the literature, we examined the association between psychotropic medications and cognitive functioning in a cohort of 567 adults with bipolar disorder receiving care in community-based psychiatric programs.

Methods

Study population

Participants were recruited at Sheppard Pratt, a large private, non-profit, community-based psychiatric health care system in central Maryland, USA. Participants were enrolled between June 2001 and June 2023 in one of several studies as shown in the Supplement Table 1. The inclusion criteria for all of the study protocols were: (1) diagnosis of bipolar disorder (type 1, type II, or not otherwise specified) meeting criteria in the Diagnostic and Statistical Manual of Mental Disorder Fourth Edition (DSM-IV, 1994) disorders (SCID) (First et al. 1996) supplemented by information from medical records; (2) age 18–65; (3) fluency in English. Exclusion criteria for all of the protocols were: (1) history of intravenous substance abuse; (2) diagnosis of childhood intellectual disability; (3) clinically significant medical disorder that would affect cognitive performance such as epilepsy, HIV, history of encephalitis or serious head trauma, or any other reported neurological disorder of the central nervous system; (4) primary diagnosis of substance abuse or dependence within the past three months; (5) receipt of electroconvulsive therapy (ECT) in the previous one month.

Demographic and clinical measures

Participants were interviewed and medical charts reviewed; information was obtained about demographic variables, current tobacco smoking, history of substance use, psychiatric history and other clinical variables as shown in Table 1. Psychiatric symptoms were assessed with the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham 1962), the Hamilton Depression Rating Scale (Hamilton 1967), and the Young Mania Rating Scale (Young et al. 1978). Body mass index (BMI) was calculated from measured weight and height.

Table 1.

Demographic, Clinical, and cognitive Characteristics, and medications received by at least 5% of the sample (N = 567)1

Demographic Variables
Age at enrollment, years 35.6 ± 13.0

Race

White

Black

Other

418 (74%)

109 (19%)

40 (7%)

Female sex 393 (69%)

Marital status

Single, never married

Married

Separated, divorced, or widowed

332 (59%)

118 (21%)

117 (21%)

Education

<12 years

High school graduate only

Some college

College graduate

71 (13%)

126 (22%)

188 (33%)

182 (32%)

Foreign born 30 (5%)

Maternal education

< 8 years

>=8 yrs - <12 years

>=12 years - < 16 years

>= 16 years

41 (7%)

231 (41%)

219 (39%)

76 (13%)

Bipolar disorder diagnosis 2

Bipolar disorder type 1

Bipolar disorder type 2

Bipolar disorder NOS

480 (85%)

71 (13%)

16 (3%)

Clinical Variables

Care setting

Outpatient

Day hospital

Inpatient unit

338 (60%)

59 (10%)

170 (30%)

Age of mood disorder onset 18.2 ± 9.1
Duration of illness, years 17.0 ± 13.2
BPRS total score 3 44.9 ± 9.3
Ham-D total score 4 19.9 ± 10.9
Young Mania Rating Scale 5 11.5 ± 8.6
Herpes simplex virus type 1 – seropositive 6 238 (42%)
C-reactive protein level, ug/ml 7 6.81 ± 9.6

Substance use history 8

1 No history of substance misuse

2 Substance misuse but not in past 3 mos.

3 Substance misuse in past 3 mos.

191 (34%)

240 (42%)

136 (24%)

Tobacco smoker 205 (36%)

Packs of cigarettes per day (ppd)

None

< 0 - <=0.5 ppd

> 0.5 - <=1.0 ppd

> 1 ppd

362 (64%)

119 (21%)

62 (11%)

24 (4%)

Caffeine use 9 485 (86%)
Body Mass Index 10 30.02 ± 7.2
Diagnosis of diabetes 11 54 (10%)
Cognitive Assessment
RBANS 12 Total 77.7 ± 14.4
RBANS 12 Immediate Memory 82.3 ± 17.2
RBANS 12 Visuospatial/Constructional 75.6 ± 15.3
RBANS 12 Attention 81.3 ± 17.4
RBANS 12 Language 91.0 ± 14.8
RBANS 12 Delayed Memory 80.6 ± 17.5
WAIS III Letter-Number Sequencing 13 8.4 ± 2.9
Trail Making Test, part A 13 8.1 ± 2.6
Psychotropic Medications 14
Antipsychotic Medications
Olanzapine - oral 71 (13%)
Quetiapine 113 (20%)
Risperidone - oral 102 (18%)
Aripiprazole - oral 79 (14%)
Ziprasidone 32 (6%)
Antidepressant Medications
Bupropion 60 (11%)
Trazodone 59 (10%)
Escitalopram 34 (6%)
Mood Stabilizing Medications
Carbamazepine 33 (6%)
Gabapentin 48 (8%)
Lamotrigine 92 (16%)
Lithium carbonate 198 (35%)
Valproate 176 (31%)
Anticholinergic Medication
Benztropine 55 (10%)
Anxiolytic and Hypnotic Medications
Clonazepam 84 (15%)
Lorazepam 29 (5%)

1 Mean ± s.d. or number (%); all variables listed in the table were included as covariates except for the

cognitive variables which were the outcomes

2 DSM IV criteria

3 BPRS, Brief Psychiatric Rating Scale

4 Ham-D, Hamilton Depression Rating Scale, 41 values imputed

5 58 values imputed

6 3 values imputed

7 177 values imputed

8 108 values imputed

9 1 value imputed

10 168 values imputed

11 2 values imputed

12 RBANS, Repeatable Battery for the Assessment of Neuropsychological Status

13 Scaled scores, 75 values imputed

14 Medications received by at least 5% of the study sample

Medications

The psychotropic medications and dosage of each psychotropic medication prescribed to the participant on the day of the study visit were obtained from available medical records and participant interviews.

Cognitive assessment

At the study visit, participants were administered a cognitive test battery, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (Randolph et al. 1998), Form A. The RBANS was selected for the measurement of cognitive functioning since it is sensitive to the level and type of cognitive impairments which are often found in individuals with bipolar disorder (Wilk et al. 2004). Test indexes are Immediate Memory (comprised of List Learning and Story Memory tasks); Visuospatial/Constructional (comprised of Figure Copy and Line Orientation tasks); Language (comprised of Picture Naming and Fluency tasks); Attention (comprised of Digit Span and Coding tasks); and Delayed Memory (comprised of List Recall, Story Recall, Figure Recall, and List Recognition tasks). Each index score is expressed as an age-adjusted standard score with a mean of approximately 100 and a standard deviation of approximately 15, based on a previously described normative study group of 540 healthy subjects, ranging in age from 20 to 89, matched to the U.S. Census on gender, ethnicity, and level of education. The index scores are combined to yield a Total RBANS score which is a measure of overall cognitive functioning.

Participants were also administered Letter-Number Sequencing, a working memory task from the Wechsler Adult Intelligence Scale III (WAIS III) (Wechsler 1997); scores were recorded as age-adjusted scaled scores. In addition, participants were administered part A of the Trail Making Test (Trails A), a task of visual scanning and motor speed (Reitan 1979); scores were recorded as scaled scores.

Serological assessment

Participants had a blood sample drawn which was employed to measure antibodies to Herpes Simplex Virus type 1 employing a type-specific enzyme immunoassay. The results were classified as positive or negative based on comparison with a standard sample included in each assay run as previously described (Dickerson et al. 2003). This antibody was chosen for measurement based on previous studies documenting its association with cognitive functioning in individuals with bipolar disorder (Dickerson et al. 2004a, b, c, 2006). The blood sample was also used to measure the level of C-reactive protein which we have also found to be associated with cognitive functioning in this populations (Dickerson et al. 2013).

Statistical analysis

In this cross sectional study, we employed the machine-learning tool of cross-fit partialing-out least absolute shrinkage and selection operator (LASSO) regression to measure the association between cognitive functioning as measured by the RBANS Total Score and index scores and the receipt of psychotropic medications along with relevant covariates (Zhang et al. 2010). The medications evaluated included all those received by at least 5% of the population at time of assessment. This method of statistical analysis was chosen since it allows for the identification of the independent associations of multiple variables of interest and covariates in an efficient manner with a minimum of confounding. Missing data in the covariates were estimated using multiple imputations. The variables included as covariates along with the number of imputed values are shown in Table 1. Missing data were supplied by multiple imputation as previously described (Dickerson et al. 2025).

The initial LASSO regression model examining RBANS Total score included all the demographic and clinical variables as well as all the 16 medications listed in Table 1.

The LASSO regression models were used to assign regression coefficients, 95% confidence intervals, and probability estimates (p values) (Chernozhukov et al. 2015). All statistical procedures were performed using the “xporegress” and “test” algorithms available in STATA version 19.5. Significance levels (p values) generated by the LASSO models were adjusted to q values reflective of multiple comparisons using the false discovery method of Benjamini et al.(Benjamini et al. 2006) (Benjamani and Hochberg 1995). A q value of ≤ 0.05 was considered to represent statistical significance in light of the multiple medications which were evaluated.

Medications significantly associated with the RBANS Total, Trails A, or Letter-Number Sequencing score were further analyzed by dosage group. The dosage levels tested are depicted in Supplement Table 2. LASSO models were employed to determine coefficients and 95% confidence intervals for the dosage levels for all of the cognitive measures employing the same covariates as the original LASSO models. Ordered logistic regression models using the same covariates were employed to determine significance levels which were adjusted using the false discovery method described above.

Results

A total of 567 participants were enrolled in the study; their demographic and clinical characteristics are depicted in Table 1; there were 16 psychotropic medications that were received by at least 5% of the study population. The total number of psychotropic medications received by study participants is presented in Supplement Table 3.

We employed cross-fit partialing-out LASSO regression models to examine the relationship between RBANS Total score and the covariates and medications listed in Table 1. As depicted in Fig. 1, this model identified significant independent associations between a lower RBANS Total score and the receipt of 3 of the psychotropic medications analyzed. These medications were: ziprasidone (coefficient − 4.87, 95% CI −8.45, −1.29, p=.008, q=0.039); benztropine (coefficient − 7.38, 95% CI −11.08, −3.68, p = < 0.001, q=0.001); and clonazepam (coefficient − 5.13, 95% CI −791, −2.35, p = < 0.001, q=0.001). None of the other psychotropic medications showed a significant association with RBANS Total score in this multivariate analysis.

Fig. 1.

Fig. 1

Association between Psychotropic Medications Received by at Least 5% of the Study Population and RBANS Total Score. Means and 95% confidence intervals of the coefficients were determined by a LASSO regression model as defined in the text. Significant q values: ziprasidone, q=.039, benztropine, q=.001; clonazepam, q=.001. Note that a coefficient of −5 corresponds to a decrease of approximately 1/3 of a standard deviation based on the standard deviation of 15 for the RBANS index and total scores

We also employed similar cross-fit partialing-out LASSO regression models to examine the relationship between RBANS index scores and the receipt of the individual psychotropic medications. The RBANS index scores measure cognitive domains of Immediate Memory, Delayed Memory, Attention, Language, and Visuospatial/Constructional. As shown in Fig. 2, all 3 medications associated with RBANS Total score were also associated with lower scores on at least one RBANS index score. Receipt of ziprasidone was associated with lower performance on the Delayed Memory index score (−8.31, 95% CI −14.09, −2.54, p=.005, q=0.028). The receipt of benztropine was associated with lower performance on Immediate Memory (−11.78, 95% CI, −16.71, −6.86, p<.001, q=0.001) and Delayed Memory (−8.85, 95% CI −14.05, −3.66, p=.001, q=0.018) index scores. The receipt of clonazepam was associated with lower performance on Delayed Memory (−5.22, 95% CI −9.29, −1,16, p=.012, q=0.044) and Language (−5.50, 95% CI −8.78, −2.22, p=.001, q=0.017) index scores. None of the other medications showed a significant association with RBANS Index scores when corrected for multiple comparisons except for the receipt of olanzapine with lowered Delayed Memory (−6.50, 95% CI −11.07, −1.93, p=.005, q=0.028).

Fig. 2.

Fig. 2

Association between Individual Medications and RBANS Index Scores. Means and 95% confidence intervals of the coefficients were determined by LASSO regression models as defined in the text. 2a. Immediate Memory. Significant q value: benztropine, q=.001. 2b. Delayed Memory. Significant q values: olanzapine, q=.028; ziprasidone, q=.028; benztropine, q=.018; clonazepam, q=.044. 2c. Visuospatial/Constructional. No significant q values. 2d. Attention. No significant q values. 2e. Language. Significant q value: clonazepam, q =.017

We employed similar cross-fit partialing-out LASSO regression models to examine the relationship between Trails A score and Letter-Number Sequencing score and the receipt of the individual psychotropic medications. Trails A is a measure of visual scanning and psychomotor speed, and Letter-Number Sequencing is a measure of working memory. As shown in Fig. 3, receipt of benztropine was associated with lower performance on Trails A (−1.14, 95% CI −1.89, −0.40, p=.003, q=0.025) and Letter-Number Sequencing (−1.37, 95% CI −2.17, −0.59, p=.001, q=0.017). The receipt of clonazepam was also associated with lower performance on Trails A (−0.88, 95% CI −1.46, −0.31, p=.002, q=0.025).

Fig. 3.

Fig. 3

Association between Individual Medications and Scores on Trails A and Letter- Number Sequencing. Means and 95% confidence intervals of the coefficients were determined by LASSO regression models as defined in the text. 3a. Trails A. Significant q values: benztropine, q=.025; clonazepam, q=.025. 3b. Letter-Number Sequencing. Significant q value: benztropine, q=.017

The covariates that were also significant in the association between each cognitive measure and the medications are shown in the Supplement Table 4.

We also examined the association between dosage levels of ziprasidone, benztropine, and clonazepam and scores on RBANS Total, Trails A, and Letter-Number Sequencing. As depicted in Fig. 4, higher dosages of benztropine were associated with lower RBANS Total (q<0.001), Trails A (q<0.004), and Letter-Number Sequencing (q<0.001) scores. There were also significant associations between dosage levels of benztropine and the RBANS index scores (Fig. 4). Dosage levels of ziprasidone and clonazepam did not show significant relationships with the cognitive scores (all q>0.05).

Fig. 4.

Fig. 4

Association between Benztropine Dosage Ranges and Cognitive Scores. The relationships were calculated by LASSO and ologit regression models as described in the text. The results are based on N=565 individuals due to missing dosage information on 2 individuals. 4a. RBANS. Significant q values: RBANS Total, q=.001; Immediate Memory, q=.001; Delayed Memory, q=.001; Visuospatial/Constructional, q=.009; Attention, q=.008; Language, q=.022. 4b. Trails A and Letter-Number Sequencing. Significant q values = Trails A, q=.004; Letter-Number Sequencing, q=.001. Note that designations “<5 mg/day” refer to dosages greater than 0 and less than 5 mg/day

Discussion

We employed the machine learning tool of cross-fit partialing-out LASSO regression to examine the independent association between psychotropic medications and cognitive functioning in a cohort of 567 people with bipolar disorder enrolled from community-based psychiatric settings. Machine-learning based methods were selected for this study since they overcome limitations inherent in the use of regression models which contain large numbers of potential co-variates. Machine learning models also partially overcome issues such as overfitting, multiple collinearity and model complexity (Geloven et al. 2022) (Lu and Petkova 2014). The use of the LASSO model allowed us to efficiently incorporate the effects of several clinical, demographic, and environmental factors which can affect cognitive functioning.

We found that 3 medications, ziprasidone, benztropine, and clonazepam, were each associated with reduced RBANS Total as well as the RBANS Delayed Memory Index score. We also found that two of the medications, benztropine and clonazepam, were each associated with reduced performance on Trails A. In terms of cognitive domains, reduced memory and psychomotor speed were most associated with these medications.

Benztropine, an anticholinergic medication, was received by 10% of the individuals in our sample. Benztropine was the medication showing the strongest association with cognitive performance in our study and was independently associated with a lower score on several cognitive measures in a dose-dependent manner. Antiparkinsonian agents including benztropine are frequently prescribed to treat and prevent anti-psychotic induced extrapyramidal symptoms. While effective for the treatment and prevention of these side effects, these and other anticholinergic medications have been associated with lower cognitive performance in patients with schizophrenia, as has been reported by our group and others (Joshi et al. 2021) (Dickerson et al. 2025; Mäkipelto et al. 2024; Ogino et al. 2014). In addition, several small studies indicate that discontinuing anticholinergic agents such as benztropine in people with schizophrenia can have a beneficial effect on cognitive functioning (Desmarais et al. 2014) (Lupu et al. 2017). Also consistent with previous studies is the pervasive effect of benztropine on cognitive functioning; 2 of the RBANS index scores as well as performance on Trails A and Letter-Number Sequencing were significantly lower in people receiving benztropine (Fig. 4). The literature on anticholinergic burden in psychiatric patients has largely focused on individuals with schizophrenia, with a small number of studies in bipolar disorder (Erdogan et al. 2025; Vidal et al. 2023). The adverse effects of anticholinergic medications such as benztropine on cognition in this population may not be fully recognized.

Previous studies of the impact of pharmacologic treatment on the cognitive functioning of persons with bipolar disorder indicate that, overall, antipsychotic agents have a negative impact, especially on verbal memory (Xu et al. 2020). It has been suggested that this association may be due, in part, to the fact that the subset of people with bipolar disorder who receive antipsychotic medication may have more severe illness symptoms than those who do not. However, we adjusted for many illness-related covariates in our study, making it less likely that an association between receipt of an antipsychotic medication and reduced cognitive functioning would be affected by confounding.

Ziprasidone is a second-generation antipsychotic medication which has an indication for the treatment of schizophrenia and related psychotic symptoms, the treatment of acute manic or mixed episodes with or without psychotic features, and as an adjunct to lithium for the maintenance treatment of bipolar disorder (Mandrioli et al. 2015). In our sample, ziprasidone was significantly and inversely associated with the RBANS Total and Delayed Memory index scores. Of note, we did not find a negative effect of ziprasidone in a previous study in schizophrenia using essentially identical statistical methods (Dickerson et al. 2025), suggesting differences between schizophrenia and bipolar disorder in the effect of individual anti-psychotic agents on cognitive functioning.

Ziprasidone has been shown to be an effective antipsychotic agent with fewer metabolic side effects and a lower risk for hyperprolactinemia than some other atypical antipsychotic agents (Mandrioli et al. 2015). However, its effects on cognitive functioning in bipolar disorder have not been widely investigated. Early studies in schizophrenia with relatively small samples and short-term follow-up periods or open label designs suggested that ziprasidone improved overall cognitive performance in the domains of verbal memory and executive functioning (Veelen et al. 2010; Gibel and Ritsner 2008). However, as more studies accumulated, these findings were not sustained. Results of a recent meta-analysis on the effects of individual antipsychotic medications vs. placebo on cognitive functioning in stable outpatients with schizophrenia did not find any cognitive enhancing effect of ziprasidone (Feber et al. 2025). However, other meta-analyses, comparing the cognitive effects of individual second-generation antipsychotics to those of each other, found that ziprasidone performed better than other antipsychotics on composite cognitive score, working memory, and verbal learning (Nielsen et al. 2015) (Baldez et al. 2021). This finding is inconsistent with the results of our current study in bipolar disorder in which persons receiving ziprasidone, and not any of the other antipsychotics, had worse performance in overall cognition and a memory measure. It is of note that the finding in the previous study was based largely on individuals with schizophrenia-spectrum disorders whose characteristics likely vary from the persons with bipolar disorder in our study. In addition, our study population was comprised of persons in routine care settings, most of whom were receiving multiple psychotropic medications. In controlled research studies, which form the bases of most of the meta-analyses, study samples are highly selected, and persons typically receive monotherapy, not the varied combinations of medication that are common in clinical practice.

Clonazepam, the third medication which was significantly associated with worse cognitive performance in our study, is a benzodiazepine and commonly used to treat symptoms of panic disorder, severe anxiety, and seizures. The effects of benzodiazepines on cognition have been studied mostly in elderly populations but not specifically persons with bipolar disorder. As a group, these medications have not been consistently associated with adverse cognitive effects, although, in one study, long-term use was associated with relatively greater cognitive decline (Edinoff et al. 2021). There are few studies of the cognitive effects of clonazepam specifically though there is some evidence that it is associated with psychomotor impairment in the elderly (Bierman et al. 2007) (Dokkedal-Silva et al. 2019). In our study, we found an adverse effect of clonazepam on Total RBANS score. We also found a significant association between the receipt of clonazepam and lower performance on Trails A, a task of psychomotor speed. It is of note that other anxiolytic medications, such as lorazepam, were not associated with lower scores on the cognitive measures. The reason for this difference is not known with certainty but may be related to the longer half-life of clonazepam with the potential for drug accumulation over long-term exposure (Greenblatt et al. 1987).

To our knowledge, there are few previous studies examining the dose-related effects of psychotropic medications on cognition in bipolar disorder. It is possible that the higher doses of benztropine associated with worse overall cognitive scores were indicative of more severe psychiatric symptoms leading to the prescription of increased doses, confounding by indication.

An explanation for the adverse effect of these medications on cognitive functioning in bipolar disorder is not known with certainty but may be related to the biological properties of these medications as well as their combined effects on critical neurotransmitter systems and brain regions. These medications disrupt the balance of multiple neurotransmitter pathways, including dopaminergic, GABAergic, and cholinergic systems, all of which are integral to cognitive function. Benztropine’s strong anticholinergic effects disrupt acetylcholine signaling, which may contribute to cognitive impairments (Joshi et al. 2021). Benzodiazepines enhance GABAergic function resulting in widespread CNS depressant effects causing sedation with inattention, and chronic use of these medications has been associated with cognitive deficits (Stewart 2005). Clonazepam is one of the most potent and longest acting benzodiazepines (Chouinard 2004). More extensive consideration of these issues is found in other publications (Feber et al. 2025; Joshi et al. 2021; Chandramouleeshwaran et al. 2024; Risacher et al. 2016).

It is also of note that we did not find any significant relationship between the receipt of lithium and any of the cognitive scores in our sample. The association between lithium and cognition in bipolar disorder has been investigated without consistent findings. Differences among study samples, dose levels, and study designs may account for the different results across studies (Xu et al. 2020; Paterson and Parker 2017).

Strengths of our study include the relatively large sample of people with bipolar disorder, the comprehensive and thorough collection of medication data, standardized protocol and data collection procedures, and standardized and consistent cognitive test scoring throughout the study period. In addition, we applied a machine learning data analytic method that allowed for the inclusion of many covariates. In addition, we were able to analyze the effects of several medication dose ranges. We also had few exclusions to study participation, so our population was likely representative of people with bipolar disorder receiving care in routine, community (non-academic) outpatient and inpatient settings, albeit not including those with recent moderate or severe alcohol or other substance misuse.

Limitations of our study include that the medications analyzed were only those which were received by at least 5% of the study population, so the possible effects of some of the less frequently used medications were not included in the analysis. While the severity of mood symptoms was taken into account in the analyses, we note that participants in the study were in varying mood states and were not all euthymic at the time of cognitive testing. Sample size precluded our ability to study the effects of medication combinations. We also did not have a measure of medication adherence or medication blood levels; however, participants were receiving psychiatric care, and the significant dose-related association with benztropine gives some credence to the findings. In addition, due to the cross-sectional nature of our study, we could not examine the effects of medications on changes in cognitive functioning over time, nor did we include measures of social functioning or medication history. Furthermore, while we controlled for a large number of variables, it is possible that unmeasured variables could contribute to the associations with cognitive functioning. For example, we did not measure total anticholinergic burden of the medications received or patient effort on cognitive tests which can affect cognitive test performance (Joshi et al. 2021) (Morra et al. 2015). Also, while our sample was relatively large, we were underpowered in terms of the ability to examine some relevant factors such as the role of polypharmacy, the dosing regimens of some of the medications, and a history of psychosis. Finally, the medications were not administered following a research protocol but were prescribed by clinicians in community programs based on their clinical judgement. However, we believe that this is also a strength of our study in that it reflects the experience of people with bipolar disorder in real-world settings.

Conclusions

We identified 3 psychotropic medications, ziprasidone, benztropine, and clonazepam, that are associated with poorer cognitive functioning in people with bipolar disorder in community-based care. While these medications have their benefits, prescribers may consider limiting the use of medications which can alter cognitive functioning. Additional interventions, both pharmacologic and psychosocial, should be further developed and evaluated for people with bipolar disorder to improve their cognitive functioning and their quality of life.

Supplementary Information

Supplementary Material 1 (26.8KB, docx)

Acknowledgements

Not applicable.

Author contributions

FD planned the study, acquired financial support for the study, administered the project, and prepared the initial draft of the manuscript; AO created the data set, curated the data, and oversaw the scoring of the cognitive tests; EK supervised the acquisition of the data; KR performed the research interviews and cognitive testing and collected data; SK performed the research interviews and cognitive testing and collected data; AC performed the research interviews and cognitive testing and collected data; FM supervised the diagnostic classification of patients and interpreted the medication data; Robert Yolken analyzed the data and prepared the visualization/data presentation of the results. All authors critically reviewed the manuscript and approved the final draft.

Funding

This work was supported by grant 07R-1690 from the Stanley Medical Research Institute (F Dickerson, PI).

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The studies were approved by the Institutional Review Boards of Sheppard Pratt and the Johns Hopkins Medical Institutions following established guidelines. All participants provided written informed consent after the study procedures were explained.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. Baldez DP, Biazus TB, Rabelo-da-Ponte FD, Nogaro GP, Martins DS, Kunz M, et al. The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: network meta-analyses of randomized controlled trials. Neurosci Biobehav Rev. 2021;126:265–75. [DOI] [PubMed] [Google Scholar]
  2. Baune BT, Malhi GS. A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder. Bipolar Disord. 2015;17(Suppl 2):41–55. [DOI] [PubMed] [Google Scholar]
  3. Benjamani Y, Hochberg Y. Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289–300. [Google Scholar]
  4. Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika. 2006;93(3):491–507. [Google Scholar]
  5. Bierman EJ, Comijs HC, Gundy CM, Sonnenberg C, Jonker C, Beekman AT. The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriatr Psychiatry. 2007;22(12):1194–200. [DOI] [PubMed] [Google Scholar]
  6. Cañada Y, Sabater A, Sierra P, Balanzá-Martínez V, Berk M, Dodd S, et al. The effect of concomitant benzodiazepine use on neurocognition in stable, long-term patients with bipolar disorder. Aust N Z J Psychiatry. 2021;55(10):1005–16. [DOI] [PubMed] [Google Scholar]
  7. Chandramouleeshwaran S, Khan WU, Inglis F, Rajji TK. Impact of psychotropic medications on cognition among older adults: a systematic review. Int Psychogeriatr. 2024;36(12):1110–27. [DOI] [PubMed] [Google Scholar]
  8. Chen WY, Liu HC, Cheng YC, Li H, Huang CC, Ding YW, et al. Effect of Pharmacological and neurostimulation interventions for cognitive domains in patients with bipolar disorder: A systematic review and network Meta-Analysis of randomized controlled trials. Clin Epidemiol. 2021;13:1039–49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chernozhukov V, Hansen C, Spindler M. Post-selection and post-regulation inference in linear models with many controls and instruments. Am Econ Rev. 2015;105(5):486–90. [Google Scholar]
  10. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(Suppl 5):7–12. [PubMed] [Google Scholar]
  11. Daglas R, Cotton SM, Allott K, Yücel M, Macneil CA, Hasty MK, et al. A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: a 12-month follow-up study. Eur Psychiatry. 2016;31:20–8. [DOI] [PubMed] [Google Scholar]
  12. Desmarais JE, Beauclair L, Annable L, Bélanger MC, Kolivakis TT, Margolese HC. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol. 2014;4(6):257–67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Ruslanova I, Yolken RH. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry. 2003;60(5):466–72. [DOI] [PubMed] [Google Scholar]
  14. Dickerson F, Boronow JJ, Stallings C, Origoni AE, Cole SK, Yolken RH. Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status. Psychiatry Res. 2004a;129(1):45–53. [DOI] [PubMed] [Google Scholar]
  15. Dickerson FB, Boronow JJ, Stallings CR, Origoni AE, Cole S, Yolken RH. Association between cognitive functioning and employment status of persons with bipolar disorder. Psychiatr Serv. 2004b;55(1):54–8. [DOI] [PubMed] [Google Scholar]
  16. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Cole S, Krivogorsky B, et al. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol Psychiatry. 2004c;55(6):588–93. [DOI] [PubMed] [Google Scholar]
  17. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Cole S, Leister F, et al. The catechol O-methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene-environmental effects in a complex human psychiatric disorder. Bipolar Disord. 2006;8(2):124–32. [DOI] [PubMed] [Google Scholar]
  18. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150(2):456–9. [DOI] [PubMed] [Google Scholar]
  19. Dickerson F, Origoni A, Katsafanas E, Rowe K, Khan S, Calahatian AT, et al. The association between psychotropic medications and cognitive functioning in a real-world cohort of 869 individuals with schizophrenia. Schizophr Bull. 2025. 10.1093/schbul/sbaf047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Dokkedal-Silva V, Berro LF, Galduróz JCF, Tufik S, Andersen ML. Clonazepam: indications, side effects, and potential for nonmedical use. Harv Rev Psychiatry. 2019;27(5):279–89. [DOI] [PubMed] [Google Scholar]
  21. Edinoff AN, Nix CA, Hollier J, Sagrera CE, Delacroix BM, Abubakar T, et al. Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int. 2021;13(4):594–607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Erdogan NO, Yucens B, Tumkaya S. Impact of anticholinergic burden on cognitive functions in individuals with bipolar disorder, schizoaffective disorder, and schizophrenia. Clin Psychopharmacol Neurosci. 2025;23(1):76–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I, et al. Antipsychotic drugs and cognitive function: A systematic review and network Meta-Analysis. JAMA Psychiatry. 2025;82(1):47–56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. First M, Gibbon M, Spitzer RL, Williams JBW. User’s Guide for the SCID-I, Structured Clinical Interview for DSM IV Axis I Disorders. New York, NY: Biometrics Research; 1996. [Google Scholar]
  25. Flaaten CB, Melle I, Bjella T, Engen MJ, Åsbø G, Wold KF, et al. Long-term course of cognitive functioning in bipolar disorder: a ten-year follow-up study. Bipolar Disord. 2024;26(2):136–47. [DOI] [PubMed] [Google Scholar]
  26. Gibel A, Ritsner MS. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Clin Neuropharmacol. 2008;31(4):204–20. [DOI] [PubMed] [Google Scholar]
  27. Greenblatt DJ, Miller LG, Shader RI. Clonazepam pharmacokinetics, brain uptake, and receptor interactions. J Clin Psychiatry. 1987;48(Suppl):4–11. [PubMed] [Google Scholar]
  28. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278–96. [DOI] [PubMed] [Google Scholar]
  29. Joshi YB, Thomas ML, Braff DL, Green MF, Gur RC, Gur RE, et al. Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia. Am J Psychiatry. 2021;178(9):838–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Keramatian K, Torres IJ, Yatham LN. Neurocognitive functioning in bipolar disorder: what we know and what we don’t. Dialogues Clin Neurosci. 2021;23(1):29–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kurtz MM, Gerraty RT. A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state. Neuropsychology. 2009;23(5):551–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lu F, Petkova E. A comparative study of variable selection methods in the context of developing psychiatric screening instruments. Stat Med. 2014;33(3):401–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lupu AM, Clinebell K, Gannon JM, Ellison JC, Chengappa KNR. Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders. J Clin Psychiatry. 2017;78(9):e1270–5. [DOI] [PubMed] [Google Scholar]
  34. Mäkipelto V, Tuulio-Henriksson A, Hakulinen C, Niemelä S, Lähteenvuo M, Wegelius A, et al. Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia. Schizophr Res. 2024;266:118–26. [DOI] [PubMed] [Google Scholar]
  35. Mandrioli R, Protti M, Mercolini L. Evaluation of the pharmacokinetics, safety and clinical efficacy of Ziprasidone for the treatment of schizophrenia and bipolar disorder. Expert Opin Drug Metab Toxicol. 2015;11(1):149–74. [DOI] [PubMed] [Google Scholar]
  36. Mora E, Portella MJ, Forcada I, Vieta E, Mur M. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study. Psychol Med. 2013;43(6):1187–96. [DOI] [PubMed] [Google Scholar]
  37. Morra LF, Gold JM, Sullivan SK, Strauss GP. Predictors of neuropsychological effort test performance in schizophrenia. Schizophr Res. 2015;162(1–3):205–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SO, Østergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia–a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131(3):185–96. [DOI] [PubMed] [Google Scholar]
  39. Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci. 2014;68(1):37–49. [DOI] [PubMed] [Google Scholar]
  40. Overall J, Gorham D. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812. [Google Scholar]
  41. Paterson A, Parker G. Lithium and cognition in those with bipolar disorder. Int Clin Psychopharmacol. 2017;32(2):57–62. [DOI] [PubMed] [Google Scholar]
  42. Perra A, Carta MG, Primavera D, Cossu G, Locci A, Zaccheddu R, et al. An integrated cognitive remediation and recovery-oriented program for individuals with bipolar disorder using a virtual reality-based intervention: 6- and 12-month cognitive outcomes from a randomized feasibility trial. Behav Sci. 2025. 10.3390/bs15040452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Prado CE, Watt S, Crowe SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. 2018;28(1):32–72. [DOI] [PubMed] [Google Scholar]
  44. Randolph C, Tierney MC, Mohr E, Chase TN. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310–9. [DOI] [PubMed] [Google Scholar]
  45. Reitan R. Manual for administration of neuropsychological test batteries for adults and children. Arizona: Tucson; 1979. [Google Scholar]
  46. Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(6):721–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Samamé C, Durante P, Cattaneo B, Aprahamian I, Strejilevich S. Efficacy of cognitive remediation in bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Psychol Med. 2023;53(12):5361–73. [DOI] [PubMed] [Google Scholar]
  48. Schretlen DJ, Cascella NG, Meyer SM, Kingery LR, Testa SM, Munro CA, et al. Neuropsychological functioning in bipolar disorder and schizophrenia. Biol Psychiatry. 2007;62(2):179–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Solé B, Jiménez E, Torrent C, Reinares M, Bonnin CDM, Torres I, et al. Cognitive impairment in bipolar disorder: treatment and prevention strategies. Int J Neuropsychopharmacol. 2017;20(8):670–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66(Suppl 2):9–13. [PubMed] [Google Scholar]
  51. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl. 2007;434:17–26. [DOI] [PubMed] [Google Scholar]
  52. van Geloven N, Giardiello D, Bonneville EF, Teece L, Ramspek CL, van Smeden M, et al. Validation of prediction models in the presence of competing risks: a guide through modern methods. BMJ. 2022;377:e069249. [DOI] [PubMed] [Google Scholar]
  53. van Veelen NM, Grootens KP, Peuskens J, Sabbe BG, Salden ME, Verkes RJ, et al. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophr Res. 2010;120(1–3):191–8. [DOI] [PubMed] [Google Scholar]
  54. Vidal N, Brunet-Gouet E, Frileux S, Aouizerate B, Aubin V, Belzeaux R, et al. Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders: Results from the FACE-BD cohort. Eur Neuropsychopharmacol. 2023;77:67–79. [DOI] [PubMed] [Google Scholar]
  55. Wechsler D. Wecshler Adult Intelligence Scale III. San Antonio, Texas: Psychological Corporation; 1997. [Google Scholar]
  56. Wilk CM, Gold JM, Humber K, Dickerson F, Fenton WS, Buchanan RW. Brief cognitive assessment in schizophrenia: normative data for the repeatable battery for the assessment of neuropsychological status. Schizophr Res. 2004;70(2–3):175–86. [DOI] [PubMed] [Google Scholar]
  57. Xu N, Huggon B, Saunders KEA. Cognitive impairment in patients with bipolar disorder: impact of Pharmacological treatment. CNS Drugs. 2020;34(1):29–46. [DOI] [PubMed] [Google Scholar]
  58. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35. [DOI] [PubMed] [Google Scholar]
  59. Zhang Y, Li R, Tsai C-L. Regularization parameter selections via generalized information criterion. J Am Stat Assoc. 2010;105:312–23. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 1 (26.8KB, docx)

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.


Articles from International Journal of Bipolar Disorders are provided here courtesy of Springer

RESOURCES